Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 Post author:Sam Post published:February 1, 2018 Post category:BioPharma Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace You Might Also Like 3 Big Drugmakers With Huge Catalysts on the Horizon January 30, 2018 PENTAX Medical Launches New Slim Linear Ultrasound Endoscope August 8, 2017 Theranos Quietly Settles Lawsuits With One of Its Biggest Investors May 1, 2017